Abstract:BACKGROUND: Despite the advances in the treatment of chronic hepatitis B virus (HBV) infection, liver transplantation (LT) remains the only hope for many patients with end-stage liver diseases resulting from HBV.OBJECTIVES: The aim of this study was to investigate the rate of HBV recurrence in cases that had undergone LT due to the HBV related liver cirrhosis.PATIENTS AND METHODS: Forty-nine patients who underwent LT due to HBV related cirrhosis since 2001 to 2009 in Shiraz Organ Transplantation Center were enrolled in the present study. They were asked to complete the planned questionnaire and also to sign the informed consent in order to take part in this study. Post-transplant prophylaxis protocol against HBV recurrence was based on a hundred milligrams of lamivudine daily plus intramuscular injections of hepatitis B immune globulin (HBIG) with appropriate dosage to keep anti-HBs antibody titer above 300 IU/L and 100 IU/L in the first six months and afterwards, respectively. Blood samples were obtained and checked for HBsAg, HBeAg, and the titers of Anti -HBsAb as well as Anti- HBeAb with ELISA. A quantitative HBV DNA assay was also done on all samples (GENE-RAD® Real-time PCR).RESULTS: There were 91.8% males and 8.2% females enrolled in the study. The duration of post-transplant prophylaxis ranged from 3 months to 8 years (mean 18.9 ± 19.3 months). HBsAg and HBeAg were positive in 24.5% and 2% of cases, respectively. Real-time PCR for HBV DNA were zero copies/mL in 91.8% of patients, none of which represented a positive value for HBV recurrence (Positive > 10,000 copies/mL). The mean Anti-HBs Ab titer was 231.7 ± 135.9 IU/L; it was above 100 IU/L in 71.4% of patients. Thirty-seven (75.5%) of the patients were taking tacrolimus plus mycophenolate mofetil, 6 (12.2%) were on cyclosporine plus mycophenolate mofetil, and 6 (12.2%) were taking sirolimus plus mycophenolate mofetil. HBsAg was detectable in seven patients taking tacrolimus plus mycophenolate mofetil (18.9%), in four patients taking cyclosporine plus mycophenolate mofetil (66.7%), and in one patient among the six who were taking sirolimus plus mycophenolate mofetil (16.7%). There was no significant statistical correlation between the presence of a positive value for HBsAg and the immunosuppression regimen or Anti HBsAb titer (P ˃ 0.05). Presence of a positive value for HBsAg was not predictive of a positive HBV DNA or its level in blood (P ˃ 0.05).CONCLUSIONS: Post-transplant HBV prophylaxis with lamivudine and intramuscular HBIG with appropriate dosage to keep anti-HBs antibody titer above 300 IU/L in the first six months and above 100 IU/L afterwards is effective for prevention of HBV recurrence after LT.

Liver Transplant in Patients With Autoimmune Hepatitis: A Large Single-Center Study.

Long-term outcomes of patients with autoimmune hepatitis induced cirrhosis after immunosuppressive treatment

Liver Transplant for Hepatocellular Carcinoma in Post-Milan Criteria Era: A Long-Term Single-Center Experience.

Impact of Human Leukocyte Antigen Matching on Hepatitis B Virus Recurrence after Liver Transplantation.

A Retrospective Analysis of Liver Transplantation in Treating Endstage Autoimmune Liver Disease

Prognostic analysis of liver transplantation in treating patients with end-stage autoimmune liver disease

Autoimmune hepatitis and liver transplantation: Indications, and recurrent and de novo autoimmune hepatitis

Increasing Prevalence and High Survival Rate of Liver Transplanted Patients with NASH and PSC Cirrhosis

P- 37 CLINICAL EVOLUTION OF PATIENTS WITH AUTOIMMUNE LIVER DISEASES IN A LIVER TRANSPLANTATION CENTER

Clinical Features, Treatment Challenges and Outcomes of Patients with Autoimmune Hepatitis: Five Years Experience in Rīga East University Hospital

Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

Waitlist and transplant outcomes in patients with metabolic dysfunction-associated steatotic liver disease and autoimmune hepatitis

Autoimmune hepatitis: Clinical characteristics and predictors of biochemical response to treatment

Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?

The differences in post-liver transplant outcomes of patients with autoimmune hepatitis who present with overlapping autoimmune liver diseases

Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response

Autoimmune Hepatitis with Acute Presentation: Clinical, Biochemical, and Histological Features of 126 Patients

P- 62 RELAPSE OF AUTOIMMUNITY IN PATIENTS WITH LIVER TRANSPLANTATION FOR AUTOIMMUNE HEPATOPATHY AT A COLOMBIAN HEPATOLOGY CENTER

[Liver transplantation program at the Burnasyan Federal Biophysical Center: experience in 500 procedures]

Antibody-Mediated Rejection in Liver Transplantation: Immuno-Pathological Characteristics and Long-Term Follow-Up